https://www.selleckchem.com/pr....oducts/Camptothecine
r GE ≥6.0mm or male participants were less likely to show complete improvement at 4 weeks. The individual effect of the average dose of BTX-A treatment for GS was GS severity and patient's ****, rather than GS etiology and other individual factors. Further, female participants with baseline anterior GE less then 5.3 mm were more likely to show complete improvement after 4 weeks of this average dose of BTX-A treatment. However, female participants with baseline anterior GE ≥6.0 mm or male participants were less likely to show comple
پسند
تبصرہ
بانٹیں
